Meridian Bioscience Congratulates Catherine Lufkin For Receiving Pure Earth's 2025 'Force Of Nature' Award
CINCINNATI, March 6, 2025 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, proudly congratulates Catherine Lufkin, Senior Director, Global Point of Care, on being honored with Pure Earth's 2025 'Force of Nature' Award. This prestigious recognition celebrates her leadership and dedication to advancing environmental health, particularly in the fight against lead poisoning.
Lufkin is being recognized at Pure Earth's International Women's Day celebration for her unwavering commitment to ensuring access to fast, accurate blood lead testing in communities impacted by lead contamination. Her leadership has been instrumental in Meridian's partnership with Pure Earth, which has provided LeadCare® II blood lead testing technology to under-resourced communities worldwide since 2016. Her dedication to advancing lead testing was also a driving force behind Meridian winning the CDC's Lead Detect Prize, a prestigious competition that fostered the development of innovative, rapid lead detection technologies to enhance public health efforts.
'We are immensely proud of Catherine's achievements and this well-deserved recognition,' said Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics. 'Her work exemplifies our mission to improve global health through innovation and collaboration. In our ongoing partnership with Pure Earth, we remain committed to reducing lead exposure and its harmful effects on vulnerable populations.'
The LeadCare II system, the only CLIA-waived point-of-care blood lead testing system, is a vital tool in Pure Earth's global efforts to combat lead poisoning. It enables rapid, reliable testing, allowing for timely intervention and treatment. Through strategic collaboration, Meridian and Pure Earth continue working to expand access to testing in communities with high lead exposure risks, helping to safeguard children's and families' health worldwide.
'I am deeply honored to receive the 'Force of Nature' Award from Pure Earth,' said Catherine Lufkin. 'Lead exposure is a preventable public health crisis, and I am proud to contribute to efforts that bring vital testing solutions to those who need them most. This award underscores the power of partnership in driving meaningful change.'
Meridian Bioscience remains steadfast in supporting initiatives to reduce the global burden of lead poisoning. Through continued innovation and collaboration, the company is dedicated to protecting public health and improving lives, one person and one test at a time.
About Pure Earth
Founded in 1999, Pure Earth is a global leader in developing evidence-based solutions to mercury and lead pollution. Committed to transparency, collaboration, measurable impact, and technical excellence, we work with partners worldwide to tackle the root causes of these toxic threats.
Our focus is protecting the most vulnerable—children and pregnant women living in toxic hotspots—by breaking the multigenerational cycle of poisoning that persists in many low- and middle-income countries. Through strategic partnerships with governments, communities, and industry, we identify and implement solutions that prevent toxic exposures, safeguard health, and restore contaminated environments.
Learn more about Pure Earth's work to improve women's health at www.pureearth.org/womens-environmental-health/
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian's website address is www.meridianbioscience.com.
Courtney Schulz
Meridian Bioscience, Inc.
Phone: 513.991.1091
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
26 minutes ago
- Medscape
Add-On D-Serine Shows Promise in Severe Depression
D-serine as an adjunctive treatment did not outperform placebo overall in patients with major depressive disorder (MDD), a new trial showed. However, depressive symptoms and anhedonia were significantly alleviated among patients with severe MDD, particularly among those on higher doses of standard medications. METHODOLOGY: Researchers conducted a 6-week, randomised, double-blind, placebo-controlled trial including 44 adult inpatients (mean age, 43.55 years; 45% women) diagnosed with moderate to severe MDD from Basel, Switzerland. Participants were randomly assigned in a 1:1 ratio to receive either D-serine (2 g/d) or placebo alongside standard treatment. The primary outcome was the change in clinician-rated depressive symptoms from baseline to post-intervention, measured using the 17-item Hamilton Depression Rating Scale. Secondary outcomes were self-reported depressive symptoms, anxiety, and anhedonia, measured using the Beck Depression Inventory-II, State-Trait Anxiety Inventory-1, and Snaith-Hamilton Pleasure Scale, respectively. TAKEAWAY: Both D-serine and placebo groups showed a significant reduction in symptoms across all measures, with no significant differences observed in the overall sample. In the subgroup analysis, D-serine significantly alleviated depressive symptoms in participants with severe MDD ( P = .02), with a trend towards reduction in anhedonia. = .02), with a trend towards reduction in anhedonia. In the D-serine group, clinical improvements were correlated with higher baseline depression severity and higher doses of standard medication. No serious adverse events were reported. IN PRACTICE: "DS [D-serine] may offer therapeutic benefits for patients with severe MDD, particularly when used alongside greater doses of TAU [treatment as usual] medication. These findings support the potential of DS as a synergistic adjunctive strategy to enhance the therapeutic effect of pharmacological interventions, especially in severe cases," the authors wrote. SOURCE: This study was led by Lukas Sempach, University of Basel, Basel, Switzerland. It was published online on May 26 in the Journal of Affective Disorders . LIMITATIONS: The small sample size limited the study's generalisability and reduced its power to detect small to moderate treatment effects, particularly in patients with severe depression. Additionally, the relatively low dose of D-serine used, along with its metabolism, may have limited its engagement with N-methyl-D-aspartate receptors. DISCLOSURES: This study was supported by the Gertrud Thalmann Foundation of the University Psychiatric Clinics Basel and the Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung. The authors reported having no conflicts of interest.
Business Wire
33 minutes ago
- Business Wire
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors
MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. 'Our vision is for the Edison System to become a foundational, non-invasive solution across a wide range of clinical applications,' said Mike Blue, President and CEO, HistoSonics. The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #HOPE4KIDNEY trial is expected to support a future submission for regulatory clearance to expand the use of histotripsy to treat kidney tissue/tumors. The Edison System is the first and only platform to use histotripsy, a non-thermal, non-invasive focused ultrasound technology, to mechanically liquefy tumors without surgery, radiation, or systemic therapies. Unlike invasive surgical approaches, histotripsy does not require incisions and enables real-time imaging and treatment monitoring, allowing physicians to target and control tissue destruction while sparing surrounding structures. 'Our vision is for the Edison System to become a foundational, non-invasive solution across a wide range of clinical applications,' said Mike Blue, President and CEO, HistoSonics. 'Completing enrollment in our pivotal kidney tumor trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumor types and indications. This achievement reflects the dedication of our team and clinical partners and brings us closer to transforming the treatment of solid tumors without the need for surgery.' Dr. William C. Huang, MD FACS, Professor and Vice Chair of Urology at the NYU Grossman School of Medicine serves as a principal investigator at the NYU Langone Medical Center, the top enrolling site in the trial. Dr. Huang commented, 'Histotripsy offers a novel, completely non-invasive treatment paradigm for kidney tumors that precisely images and treats tumors while preserving surrounding critical structures thereby minimizing the morbidity associated with traditional surgical and thermal ablative techniques.' Dr. Michael McDonald, Assistant Professor of Urology at the University of Central Florida College of Medicine and Urologic Surgeon at AdventHealth at Celebration Florida, serves as a principal investigator for one of the participating sites in the trial. Dr. McDonald commented, 'HistoSonics represents a paradigm shift proving that the most profound treatments for both benign and malignant diseases need not be the most invasive. The ability to precisely target and destroy tumors without scalpel or scar is the next step in the evolution of non-surgical intervention.' The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit:
Yahoo
2 hours ago
- Yahoo
Biodefense Market worth $1.81 billion by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- The biodefense market is projected to grow from USD 0.89 billion in 2025 to USD 1.81 billion by 2030 at a CAGR of 15.1% during the forecast period according to a new report by MarketsandMarkets™. The biodefense market is driven by increasing bioterrorism, growing geopolitical tensions, biological warfare risks, and advancements in technology. Biodefense encompasses a range of tools and systems designed to detect, prevent, and respond to biological threats, including infectious diseases, bioterrorism, and accidental pathogen releases. These include biosensors, rapid detection platforms, decontamination systems, mobile containment units, and AI-driven surveillance tools. The market for biodefense technology is experiencing strong growth due to increasing global concerns over pandemics, biological warfare, and emerging infectious diseases. Download PDF Brochure: Browse in-depth TOC on "Biodefense Market" 196 – Tables56 – Figures217 – Pages Biodefense Market Report Scope: Report Coverage Details Market Revenue in 2025 $ 0.89 billion Estimated Value by 2030 $ 1.81 billion Growth Rate Poised to grow at a CAGR of 15.1% Market Size Available for 2020–2030 Forecast Period 2025–2030 Forecast Units Value (USD Million/Billion) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered By Technology, Product, Application and Region Geographies Covered North America, Europe, Asia Pacific, and Rest of World Key Market Challenge Infrastructure constraints in low-resource areas Key Market Opportunities Emergence of AI-powered biosurveillance and predictive analytics Key Market Drivers Rising threat of Bioterrorism Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Hospitals are the initial point of contact for the identification of unusual infections or exposure to biological agents, and hence, they must have sophisticated containment systems, sterilization apparatus, and pathogen detection instruments in real time. With increasing bioterrorism, governments and health agencies are investing heavily in the upgrade of hospital biosafety facilities, such as Class III biological safety cabinets, mobile isolation units, and UV sterilization technology, all of which are becoming essential for modern biodefense infrastructure. These facilities need safe conditions to work with high-risk pathogens, which fuels the demand for low-temperature sterilizers, decontamination chambers, and air purification. The growing incorporation of digital surveillance platforms and smart biodefense technologies in healthcare facilities further solidifies their role in early detection and quick response, making hospitals & medical institutes the largest application segment of the biodefense market. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period due to its significant contributions toward monitoring real-time pathogens, forecasting, and fast decision-making. AI facilitates the convergence and synthesis of large-scale environmental data and enables early threat detection and quick response coordination. Governments and health organizations globally are increasingly using AI platforms to track bio-threats across borders and to automatically report disease transmission for strategic purposes. Additionally, AI technologies are being integrated into biosensor networks, autonomous disinfecting robots, and predictive modeling applications utilized in hospitals, airports, and military bases. The increasing focus on digitally empowered biodefense infrastructure, coupled with significant investments by public and private sectors, is expected to fuel the growth of the AI segment in the global market. Inquiry Before Buying: Asia Pacific is projected to register the highest CAGR during the forecast period. Asia Pacific is projected to register the highest CAGR in the biodefense industry through the forecast period due to increasing investments in public health infrastructure, infectious disease surveillance, and military biosafety capacities. China, India, Japan, and Australia are comprehensively developing their biodefense capabilities. These countries are investing in mobile biosafety laboratories, near-real-time pathogen detection systems, and next-generation decontamination technologies to anticipate future biological threats. Also, the region is experiencing growth in biotechnology R&D, cross-border health security efforts, and government-backed biodefense programs. The growth of local biotech and med-tech firms is also propelling innovation in AI-powered disease monitoring, biosensors, and portable sterilizers for civilian and military applications. The growing population, susceptibility to zoonotic disease, and proactive policy changes are driving significant growth in the regional biodefense market. STERIS (US), ASP International GmbH (a subsidiary of Fortive) (US), Ushio Inc. (Japan), Sotera Health Company (US), and Bioquell, An Ecolab Solution (UK) are the major key players in the biodefense companies. These companies have strong distribution networks across regions like North America, Europe, Asia Pacific, and the Rest of the World. Get 10% Free Customization on this Report: Browse Adjacent Market: Aerospace and Defence Market Research Reports & Consulting Related Reports: Border Security Market by Domain (Land, Maritime, Airborne), Vertical (Military, Homeland Security), System (Surveillance Systems, Detection Systems, Communication Systems, Command and Control Systems), Installation & Region – Global Forecast to 2029 CBRN Defense Market by Type (Chemical, Biological, Radiological, Nuclear, Explosives), Equipment (Protective Wearables, Respiratory Systems, Detection & Monitoring Systems, Decontamination Systems, Simulators, Others), End Use and Region - Global Forecast to 2028 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Web Site: Insight: Source: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
